Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).

O'Kane GM, Mesci A, Jang RW, Barry A, Bocaya CM, Boukhaled GM, Acton H, Doddington D, Rodrigo R, Chan LML, Noamani B, Harvey H, Elia A, Law R, Prince R, Doherty M, Dodd A, Wong DK, Wang L, Wang BX, Chen EX, Dawson LA, Knox JJ

Open source

DOI: 10.1016/j.jhepr.2025.101658
Published: 2026 Feb
Container: JHEP reports : innovation in hepatology
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jhepr.2025.101658,
  title = {Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).},
  author = {O'Kane GM and Mesci A and Jang RW and Barry A and Bocaya CM and Boukhaled GM and Acton H and Doddington D and Rodrigo R and Chan LML and Noamani B and Harvey H and Elia A and Law R and Prince R and Doherty M and Dodd A and Wong DK and Wang L and Wang BX and Chen EX and Dawson LA and Knox JJ},
  year = {2026},
  journal = {JHEP reports : innovation in hepatology},
  doi = {10.1016/j.jhepr.2025.101658},
  url = {https://doi.org/10.1016/j.jhepr.2025.101658}
}

RIS

TY  - JOUR
TI  - Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).
AU  - O'Kane GM
AU  - Mesci A
AU  - Jang RW
AU  - Barry A
AU  - Bocaya CM
AU  - Boukhaled GM
AU  - Acton H
AU  - Doddington D
AU  - Rodrigo R
AU  - Chan LML
AU  - Noamani B
AU  - Harvey H
AU  - Elia A
AU  - Law R
AU  - Prince R
AU  - Doherty M
AU  - Dodd A
AU  - Wong DK
AU  - Wang L
AU  - Wang BX
AU  - Chen EX
AU  - Dawson LA
AU  - Knox JJ
PY  - 2026
JO  - JHEP reports : innovation in hepatology
DO  - 10.1016/j.jhepr.2025.101658
UR  - https://doi.org/10.1016/j.jhepr.2025.101658
ER  -

APA

GM, O., A, M., RW, J., A, B., CM, B., GM, B., H, A., D, D., R, R., LML, C., B, N., H, H., A, E., R, L., R, P., M, D., A, D., DK, W., L, W., BX, W., EX, C., LA, D., & JJ, K. (2026). Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).. JHEP reports : innovation in hepatology. https://doi.org/10.1016/j.jhepr.2025.101658

Source records

pubmed · retrieved 2026-09-25T10:48:41.131Z
europe-pmc · retrieved 2026-09-25T10:48:41.130Z
doaj · retrieved 2026-09-25T10:48:41.107Z